China-based Hebei Viroad Biotechnology has invested €5m ($7m) in Gilupi, a Germany-based drugs developer, as part of a wider licensing agreement”for large parts of Asia”. Gilupi raised €3.6m in its series C round in January 2011. Previous investors include state- and corporate-backed early-stage investment manager High-Tech Gründerfonds (HTGF) and regional banks and state funds Aurelia…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
